From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
 | Galcanezumab 120 mg | Galcanezumab 240 mg | ||
---|---|---|---|---|
N | Mean (SE) or % | N | Mean (SE) or % | |
MSQ RF-R, mean increase (improvement) | 130 | 31.6 (1.2) | 135 | 33.4 (1.2) |
MIDAS total, mean decrease (improvement) | 124 | −33.6 (2.1) | 130 | −32.7 (2.0) |
Patient Global Impression – Illness Improvement at Month 12 | 90 | – | 112 | – |
 Very much better |  | 52.2% |  | 52.7% |
 Much better |  | 27.8% |  | 32.1% |
 A little better |  | 15.6% |  | 7.1% |
 No change |  | 3.3% |  | 7.1% |
 A little worse |  | 1.1% |  | 0.9% |
 Much worse |  | 0% |  | 0% |
 Very much worse |  | 0% |  | 0% |